URGN — UroGen Pharma Ltd.

UroGen Pharma Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $51 million, a 152% increase year-over-year from $20.3 million in Q1 2025.
• ZUSDURI Revenue: $29.2 million, representing over 100% quarter-over-quarter growth following the implementation of a permanent J-code.
• JELMYTO Revenue: $21.7 million, with stable demand and a projected full-year revenue of $97 million to $101 million.
• Net Loss: $23.6 million, or $0.47 per share, improved from a net loss of $43.8 million, or $0.92 per share, in Q1 2025.
• Cash Position: Approximately $140 million in cash, cash equivalents, and marketable securities as of March 31, 2026.

2. Strategic Updates and Business Highlights

• Leadership Changes: CEO Liz Barrett has taken direct oversight of the commercial organization, leading to enhanced agility in decision-making.
• ZUSDURI Launch: The launch is showing strong momentum, with significant growth in unique prescribers (256, up from 102) and repeat prescribers (103, up from 32).
• Market Positioning: ZUSDURI is positioned as the first FDA-approved treatment for recurrent low-grade intermediate risk non-muscle invasive bladder cancer, offering a non-surgical alternative.
• Pipeline Development: UroGen is advancing its pipeline, including UGN-103, with an NDA submission expected in H2 2026 and plans for expansion into additional bladder cancer settings.

3. Forward Guidance and Outlook

• Growth Expectations: Continued strong growth is anticipated throughout 2026, particularly in community practices where 70% of the market opportunity resides.
• Operating Expenses: Expected to be between $240 million and $250 million for the full year, with Q1 being the peak for selling, general, and administrative expenses.
• Patient Conversion: The time from patient enrollment forms to treatment initiation is improving, with expectations to reach a steady state of 2-3 weeks by the end of 2026.

4. Bad News, Challenges, or Points of Concern

• High SG&A Expenses: Selling, general, and administrative expenses rose to $51.5 million in Q1 2026, primarily due to ZUSDURI commercial activities and debt refinancing costs.
• Market Competition: Potential future competition from other therapies in the adjuvant setting for bladder cancer could impact ZUSDURI's market share.
• Patient Adoption: While initial uptake is strong, there is a need to ensure ongoing adoption and avoid being niche-focused on patients with multiple TURBTs.

5. Notable Q&A Insights

• Demand Trends: Continued growth in Q2 is expected, although not necessarily at the same acceleration seen in Q1.
• Community vs. Academic Prescribers: Over 50% of ZUSDURI users are also JELMYTO prescribers, indicating crossover usage. The company expects a 60-40 mix favoring community practices as adoption grows.
• Patient Preferences: There is anecdotal evidence of patients actively requesting ZUSDURI, indicating a shift in patient choice towards non-surgical options.
• UGN-103 Development: Plans for adjuvant trials are being finalized, with a focus on expanding UGN-103's indications in the bladder cancer treatment landscape.

This summary encapsulates the key points from UroGen Pharma's Q1 2026 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced by the company.